iCareAb is committed to the development of tumor immunotherapy technology, providing flow cytometry antibodies for multiple popular targets.

Several recombinant proteins, which are popular targets for tumor immunotherapy, are expressed using mammalian cell lines.

Provide high-quality CAR-T/TCR-T cell drug development services to meet the requirements of in vivo and in vitro pharmacodynamic evaluation experiments.